Metabolica Health
Metabolica Health Inc. is a development stage biotechnology firm focused on discovering and developing innovative treatments for diabetes and obesity. Collaborating with world-class universities, the company emphasizes products related to intestinal microbiome metabolism and aims to shape the future of metabolic health, therapeutic weight-loss, and diabetes care. It holds a valuable IP portfolio, including an issued patent from the USPTO, and is preparing to list on public exchanges in Canada and the US by 2024.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical-stage therapeutic compounds derived from gut microbiome metabolites
Preclinical compounds derived from intestinal microbiome metabolic by-products intended to improve glycemic control and reduce body weight in models of metabolic disease.
Preclinical-stage therapeutic compounds derived from gut microbiome metabolites
Preclinical compounds derived from intestinal microbiome metabolic by-products intended to improve glycemic control and reduce body weight in models of metabolic disease.
Services
Collaborative research agreements with academic institutions to advance discovery and preclinical development of metabolite-derived compounds.
Provision and publication of investor filings and presentation materials including SEDAR+ filings and a pitch deck.
Collaborative research agreements with academic institutions to advance discovery and preclinical development of metabolite-derived compounds.
Provision and publication of investor filings and presentation materials including SEDAR+ filings and a pitch deck.
Expertise Areas
- Microbiome-derived therapeutics
- Preclinical research and animal models for metabolic disease
- Metabolomics and metabolite discovery
- Mechanism-of-action studies on insulin secretion
Key Technologies
- Microbiome metabolite therapeutics
- Metabolomics / metabolite analysis
- In vivo animal efficacy models
- Glucose-stimulated insulin secretion assays